Literature DB >> 28370058

Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study.

Tai-Shuan Lai1,2, Mei-Hsuan Lee3, Hwai-I Yang4, San-Lin You5,6, Sheng-Nan Lu7, Li-Yu Wang8, Yong Yuan9, Gilbert L'Italien9,10, Kuo-Liong Chien2, Chien-Jen Chen2,4.   

Abstract

The association between hepatitis C virus (HCV) infection and end-stage renal disease (ESRD) remains controversial without considering the role of HCV viral load and genotype. This study aimed to determine whether HCV RNA level and genotype affect the risk of developing ESRD. Between 1991 and 1992, 19,984 participants aged 30-65 years were enrolled in a community-based prospective cohort study in Taiwan. Chronic HCV infection was defined by detectable HCV viral load. ESRD was determined as the need for chronic dialysis or renal transplantation. Conventional Cox proportional hazard and competing risk models were used to determine the hazard ratio (HR) for ESRD. After a median follow-up of 16.8 years, 204 cases were detected during 319,474 person-years. The incidence rates of ESRD for nonchronically HCV-infected and chronically HCV-infected patients were 60.2 and 194.3 per 100,000 person-years, respectively. The multivariable HR was 2.33 (95% confidence interval [CI] 1.40-3.89) when comparing patients with and without chronic HCV infection. Patients with low and high HCV RNA levels were at higher risk of ESRD than those who were nonchronically HCV-infected (HR, 2.11, 95% CI 1.16-3.86, and HR, 3.06, 95% CI 1.23-7.58; Ptrend < 0.001). This association remained robust after taking pre-ESRD death as a competing event for ESRD. Patients with HCV genotype 1 tended to have a higher risk of developing ESRD (HR, 3.60 95% CI 1.83-7.07) compared with nonchronically HCV-infected subjects.
CONCLUSIONS: This study reveals that chronic HCV infection is associated with an increased risk of developing ESRD and suggests that elevated serum levels of HCV RNA (>167,000 IU/mL) and HCV genotype 1 are strong predictors of ESRD, indicating clinical implications for the management of chronic HCV. (Hepatology 2017;66:784-793).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28370058     DOI: 10.1002/hep.29192

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

1.  Association between hepatitis C virus and chronic kidney disease: heterogeneity begets heterogeneity.

Authors:  Gregory M Lucas
Journal:  Kidney Int       Date:  2017-09       Impact factor: 10.612

2.  Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes.

Authors:  Jia Li; Stuart C Gordon; Loralee B Rupp; Talan Zhang; Sheri Trudeau; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Mei Lu
Journal:  Aliment Pharmacol Ther       Date:  2019-01-16       Impact factor: 8.171

3.  Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine.

Authors:  Waseem Amjad; Talan Zhang; Anurag Maheshwari; Paul J Thuluvath
Journal:  J Clin Exp Hepatol       Date:  2021-08-20

4.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Infection       Date:  2018-09-25       Impact factor: 3.553

5.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  J Nephrol       Date:  2018-09-25       Impact factor: 3.902

6.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Intern Emerg Med       Date:  2018-09-25       Impact factor: 3.397

7.  Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients.

Authors:  Melissa Corson; Ashley Moch; Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

8.  Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.

Authors:  Kati Kaartinen; Sauli Vuoti; Eero Honkanen; Eliisa Löyttyniemi; Ravinder Singh; Martti Färkkilä
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

Review 9.  Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?

Authors:  Virginia Solitano; Maria Corina Plaz Torres; Nicola Pugliese; Alessio Aghemo
Journal:  Viruses       Date:  2021-06-01       Impact factor: 5.048

Review 10.  Hepatitis C and renal transplantation in era of new antiviral agents.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  World J Transplant       Date:  2018-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.